Skip Navigation


Annals of Oncology Advance Access originally published online on November 15, 2006
Annals of Oncology 2007 18(2):263-268; doi:10.1093/annonc/mdl376
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
18/2/263    most recent
mdl376v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ferrero, J-M
Right arrow Articles by Pujade-Lauraine, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrero, J-M
Right arrow Articles by Pujade-Lauraine, E
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

gynecologic tumors

Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial

J-M Ferrero1, B Weber2, J-F Geay3, D Lepille4, H Orfeuvre5, M Combe6, F Mayer7, B Leduc8, H Bourgeois9, D Paraiso3 and E Pujade-Lauraine3,10,*

1 Centre Antoine Lacassagne, Nice
2 Centre Alexis Vautrin, Vandoeuvre-Les-Nancy
3 Hôpital Hôtel-Dieu, Paris
4 Clinique Pasteur, Evreux
5 Hôpital Fleyriat, Bourg-en-Bresse
6 Centre Hospitalier, Le Mans
7 Centre Georges François Leclerc, Dijon
8 Centre Hospitalier, Brive-La-Gaillarde
9 CHU Bretonneau, Tours
10 Université Paris Descartes, Paris, France

* Correspondence to: Dr E. Pujade-Lauraine, Département d'Hématologie et d'Oncologie Médicale, Hôpital Hôtel-Dieu, 1 Place du Parvis Notre Dame, 75004 Paris, France. Tel: +33-142-34-80-28; Fax: +33-142-34-81-10; E-mail: epujade{at}gineco.org

Background: Platinum-based chemotherapy is standard second-line treatment of patients with advanced ovarian cancer (AOC) in late relapse. Pegylated liposomal doxorubicin (PLD) has significant single-agent activity in this setting. Therefore, we evaluated the use of PLD plus carboplatin in this patient population.

Patients and methods: PLD 30 mg/m2 followed by carboplatin at area under the curve (AUC) 5 mg·min/ml, repeated every 28 days for a maximum of nine cycles, was administered to 104 women with AOC relapsing ≥6 months after completion of first- or second-line therapy with platinum-taxane-based regimens.

Results: Overall response was 63%, with a 38% complete response, median progression-free survival of 9.4 months, and median overall survival (OS) of 32 months. Grade 3 or 4 neutropenia occurred in 51% of patients, but febrile neutropenia in only 3%. Nonhematologic toxic effects were primarily grades 1 and 2, with low rates of alopecia and neurotoxicity.

Conclusions: PLD plus carboplatin is highly effective, prolongs OS, and is well tolerated in women with AOC in late relapse previously treated with both platinum and taxanes. Evaluation of this regimen in phase III trials is warranted.

Key words: liposomal doxorubicin, ovarian cancer

Received for publication May 25, 2006. Revision received August 30, 2006. Accepted for publication August 31, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.